[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Table 1. Preoperative Patient Characteristicsa
Table 1. Preoperative Patient Characteristicsa
Table 2. Patient Characteristics and Surgical Procedures
Table 2. Patient Characteristics and Surgical Procedures
Table 3. Preoperative and Postoperative VA
Table 3. Preoperative and Postoperative VA
Table 4. Preoperative and Postoperative IOP and Glaucoma Medication Therapy
Table 4. Preoperative and Postoperative IOP and Glaucoma Medication Therapy
Table 5. Preoperative and Postoperative Corticosteroid and Immunomodulatory Drug Therapy
Table 5. Preoperative and Postoperative Corticosteroid and Immunomodulatory Drug Therapy
1.
Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW.Fluocinolone Acetonide Study Group.  Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.  Ophthalmology. 2010;117(3):567-575PubMedArticle
2.
Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The Multicenter Uveitis Steroid Treatment trial: rationale, design, and baseline characteristics.  Am J Ophthalmol. 2010;149(4):550-561PubMedArticle
3.
Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results.  Arch Ophthalmol. 2008;126(9):1191-1201PubMedArticle
4.
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T.Fluocinolone Acetonide Uveitis Study Group.  Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.  Ophthalmology. 2006;113(6):1020-1027PubMedArticle
5.
Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.  Ophthalmology. 2005;112(7):1192-1198PubMedArticle
6.
Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature.  Curr Opin Ophthalmol. 2006;17(2):163-167PubMed
7.
Goldstein DA, Godfrey DG, Hall A,  et al.  Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.  Arch Ophthalmol. 2007;125(11):1478-1485PubMedArticle
8.
Chieh JJ, Carlson AN, Jaffe GJ. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.  Am J Ophthalmol. 2008;146(4):589-594PubMedArticle
9.
Malone PE, Herndon LW, Muir KW, Jaffe GJ. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.  Am J Ophthalmol. 2010;149(5):800-806, e1PubMedArticleArticle
10.
Jabs DA, Nussenblatt RB, Rosenbaum JT.Standardization of Uveitis Nomenclature (SUN) Working Group.  Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop.  Am J Ophthalmol. 2005;140(3):509-516PubMedArticle
11.
Muccioli C, Belfort R Jr. Cataract surgery in patients with uveitis.  Int Ophthalmol Clin. 2000;40(2):163-173PubMedArticle
12.
Okhravi N, Lightman SL, Towler HM. Assessment of visual outcome after cataract surgery in patients with uveitis.  Ophthalmology. 1999;106(4):710-722PubMedArticle
13.
Foster RE, Lowder CY, Meisler DM, Zakov ZN. Extracapsular cataract extraction and posterior chamber intraocular lens implantation in uveitis patients.  Ophthalmology. 1992;99(8):1234-1241PubMed
14.
Rahman I, Jones NP. Long-term results of cataract extraction with intraocular lens implantation in patients with uveitis.  Eye (Lond). 2005;19(2):191-197PubMedArticle
15.
Estafanous MF, Lowder CY, Meisler DM, Chauhan R. Phacoemulsification cataract extraction and posterior chamber lens implantation in patients with uveitis.  Am J Ophthalmol. 2001;131(5):620-625PubMedArticle
16.
Belair ML, Kim SJ, Thorne JE,  et al.  Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography.  Am J Ophthalmol. 2009;148(1):128-135PubMedArticle
17.
Hau S, Barton K. Corneal complications of glaucoma surgery.  Curr Opin Ophthalmol. 2009;20(2):131-136PubMedArticle
18.
Lee EK, Yun YJ, Lee JE, Yim JH, Kim CS. Changes in corneal endothelial cells after Ahmed glaucoma valve implantation: 2-year follow-up.  Am J Ophthalmol. 2009;148(3):361-367PubMedArticle
19.
Sarkisian SR Jr. Tube shunt complications and their prevention.  Curr Opin Ophthalmol. 2009;20(2):126-130PubMedArticle
Surgical Technique
Surgeon's Corner
July 2012

Combined Posterior Chamber Intraocular Lens, Vitrectomy, Retisert, and Pars Plana Tube in Noninfectious Uveitis

Author Affiliations

Author Affiliations: Kresge Eye Institute, Division of Vitreoretinal Surgery, Department of Ophthalmology, Wayne State University, Detroit, Michigan. Dr Mahmoud is now with Vitreoretinal Surgery, Duke University Eye Center, Durham, North Carolina.

Arch Ophthalmol. 2012;130(7):908-913. doi:10.1001/archophthalmol.2011.1425
Abstract

Objective To assess the safety and efficacy of combined cataract extraction, posterior chamber intraocular lens placement, pars plana vitrectomy, fluocinolone acetonide intravitreal implant (Retisert), and Ahmed valves with pars plana tube (CPR-PT) in eyes with chronic, posterior, noninfectious uveitis.

Methods Retrospective study of patients who underwent CPR-PT. Outcome measures included visual acuity, intraocular pressure, inflammation, and complications.

Results Eight eyes were included, with a mean follow-up of 18 months. Mean visual acuity improved from 1.89 to 0.14 logMAR (Snellen, counting fingers at 2 ft [0.6 m]) to 20/30; P = .01). Mean intraocular pressure remained stable at 16 to 17 mm Hg (P = .35). The number of glaucoma medications per eye decreased from 2.9 to 0.25 (P = .01). Systemic prednisone therapy was discontinued in all patients by 9 months postoperatively. Inflammation was well controlled in all eyes.

Conclusion The CPR-PT procedure allows rapid visual rehabilitation without major short-term complications.

Uveitis accounts for up to 10% of blindness in the United States.1 Until recently, treatment options for posterior uveitis were largely limited to short-lived periocular and intraocular corticosteroids or systemic corticosteroids and immunomodulatory drugs, which have significant potential systemic adverse effects.1,2 Intravitreal fluocinolone acetonide implants (Retisert; Bausch and Lomb Inc) allow for localized sustained release of a corticosteroid into the vitreous cavity, thus maximizing efficacy while minimizing systemic adverse effects.35 Ocular adverse effects commonly seen with fluocinolone acetonide implants include visually significant cataracts requiring surgery (93% of patients) and glaucoma (75% of patients, with 37%-40% requiring surgery).3,6,7 There have been reports8,9 of combined fluocinolone acetonide implantation and cataract extraction (CE), as well as reports of combined fluocinolone acetonide implant and glaucoma tube shunt placement; however, to our knowledge, there have been no reports to date of the 3 procedures combined. Patients with noninfectious uveitis complicated by advanced cataract and glaucoma represent an extremely challenging situation. For these complicated cases, we describe our experience with a single combined procedure of CE, posterior chamber intraocular lens (PCIOL) placement, pars plana vitrectomy (PPV), intravitreal fluocinolone acetonide implant placement (Retisert; Bausch & Lomb Inc), and pars plana tube (PPT) placement (CPR-PT). Outcome measures included visual acuity, intraocular pressure, inflammation, and complications.

METHODS

This retrospective interventional study was undertaken with institutional review board approval obtained by the Wayne State University Human Investigation Committee. All eyes with combined CPR-PT procedures performed at Kresge Eye Institute between September 1, 2007, and May 31, 2009, were included. All patients had at least 1 year of follow-up. Patients were considered for CPR-PT if they had chronic, recurrent, noninfectious posterior uveitis with advanced cataract and elevated intraocular pressure (IOP) requiring medical management (Table 1). All patients had extensive laboratory workups to rule out an infectious etiology of uveitis. Patients included were receiving a combination of periocular and/or systemic corticosteroids and immunomodulatory drugs before surgery.

SURGICAL TECHNIQUE

The operation was performed under monitored anesthesia care, with intravenous sedation and local anesthesia in the form of a retrobulbar block (50/50 mixture of lidocaine, 4%, and bupivacaine, 0.75%). Cataract extraction with synechiolysis, capsular tension ring placement in some eyes, and PCIOL placement was performed through a clear corneal approach. A 10-0 nylon suture was used to close the corneal wound to help maintain chamber stability during vitrectomy. A 360° peritomy was then performed. An infusion cannula was placed in the inferotemporal quadrant and 20-gauge PPV was carried out, during which care was taken to detach the posterior hyaloid and shave the vitreous base, relieving any peripheral traction. The sclerotomy sites were then plugged. Attention was turned to the fluocinolone acetonide implant, using the previously described surgical technique.5 Briefly, the implant was prepared on a dry surface by passing a single 8-0 double-armed polypropylene suture (Prolene; Ethicon) through the hole in the strut of the implant and tying it with a single throw. A 19-gauge microvitreoretinal blade was used to create a scleral wound inferonasally 3.5 mm posterior to the limbus and 3.5 mm wide. The implant was inserted into the vitreous cavity, and the 8-0 polypropylene suture was passed on either side of the sclera and tied in place. The implant was visualized to be inside the vitreous cavity. The sclerotomy was closed with interrupted 9-0 polypropylene sutures over the remaining long tails of the 8-0 polypropylene suture. An anterior chamber tube (Ahmed valve; New World Medical, Inc) was then secured in the superotemporal quadrant with insertion of the tube into the pars plana (PPT). The model FP7 Ahmed valve, which has a clip to angle the tube 90° for scleral insertion into the vitreous cavity, was used in some eyes. The tube was covered with a sterile pericardial patch graft (Tutoplast; Tutogen Medical). Both the fluocinolone acetonide implant and PPT were visualized in the vitreous cavity. The sclerotomies were sutured with 7-0 polyglactin 910 (Vicryl; Ethicon), and the conjunctiva was closed with 6-0 plain gut. Subconjuctival cefazolin sodium and dexamethasone sodium phosphate were administered. Postoperatively, topical and systemic corticosteroids and immunomodulatory drug therapies were slowly tapered and discontinued as tolerated.

STATISTICAL ANALYSIS

Statistical analysis was performed using commercial software (PASW Statistics, version 18; SPSS, Inc). A Wilcoxon signed rank test was used to determine statistical significance.

RESULTS

Eight eyes (5 patients) with panuveitis10 with mean follow-up of 18 months (range, 13-27 months) were included in the study. All 8 eyes received a single procedure consisting of synechiolysis, CE/PCIOL, PPV, fluocinolone acetonide implant, and Ahmed valve with PPT placement. One eye had a sulcus intraocular lens placed because of a posterior capsular tear, 4 eyes had prophylactic capsular tension rings placed, and 3 eyes had a PPT clip placed. Two eyes had preexisting anterior chamber tubes (Ahmed valves) that were diverted to the pars plana secondary to corneal erosion (Table 2).

VISUAL ACUITY

All eyes had improved visual acuity after the procedure (Table 3). All 8 eyes improved 3 or more lines, and no eyes had worsened visual acuity at any time. Mean (SD) visual acuity improved significantly from preoperative 1.89 (0.93) logMAR (Snellen, approximately counting fingers at 2 ft [0.6 m]) to postoperative 0.14 (0.15) logMAR (Snellen ~20/30) (P = .01). All 8 eyes had a visual acuity of 20/200 or worse (range, 20/200 to hand motions) preoperatively and improved to 20/40 or better (range 20/20 to 20/40) at final follow-up. Six eyes had visual acuity of 20/30 or better at final follow-up. All patients showed an intact outer segment/inner segment photoreceptor junction on postoperative spectral-domain optical coherence tomography corresponding to the recovery of visual acuity.

INTRAOCULAR PRESSURE

Intraocular pressure remained stable after surgery in all eyes (Table 4). Mean postoperative IOP (17 [5] mm Hg; range, 12-24 mm Hg) was similar to mean preoperative IOP (16 [6] mm Hg; range, 11-25 mm Hg) (P = .35). All patients were receiving fewer glaucoma drops postoperatively (mean, 0.25 [0.46] drop) than preoperatively (mean, 2.9 [0.8] drops) (P = .01). Acetazolamide was required in 1 patient (2 eyes) preoperatively and successfully discontinued after surgery. Two eyes developed pupillary block and iris bombe, which were successfully relieved with peripheral laser iridotomy. No other glaucoma procedures were required to control IOP.

CONTROL OF INFLAMMATION

Uveitis was graded using Standardization of Uveitis Nomenclature.10 There was a statistically significant decrease in the number of uveitis flares postoperatively compared with the year before surgery (P = .02). All patients had at least 1 flare (mean, 1.9 flares) in the year before surgery, but in our study group, no patient experienced a flare postoperatively.

Inflammation was well controlled (trace anterior vitreous and/or anterior chamber cell or less) in all eyes postoperatively, with no eyes requiring periocular or intraocular corticosteroid injections, systemic corticosteroids, or immunomodulatory drugs once systemic and topical medications were tapered to discontinuation (Table 5). This was in stark contrast to preoperative conditions in which all 8 eyes required systemic prednisone (mean dosage, 48 [34] mg/d; range, 5-80 mg/d; P = .01), with 5 eyes requiring large dosages of 60 to 80 mg/d, and 3 eyes required systemic immunomodulatory drugs (methotrexate sodium or azathioprine) for adequate inflammatory control. Oral prednisone was restarted postoperatively in 1 patient for treatment of nephropathy. Inflammation was well controlled in all eyes at the final follow-up visit.

COMPLICATIONS

Two eyes developed pupillary block because of 360° of posterior synechiae, which was relieved with peripheral laser iridotomy. Three eyes experienced a transient vitreous hemorrhage immediately postoperatively, which resolved within 3 weeks without sequelae. Two eyes with epiretinal membranes developed mild choroidal effusion without hypotony that spontaneously resolved within 2 weeks. One eye with lower initial IOP without hypotony showed a longer tube crossing behind the PCIOL, and this retracted slightly to a more peripheral position with normalization of the IOP. After that, we preferred an Ahmed valve with a pars plana clip to control the length of the tube in the parsplana, maintain good positioning and curvature in the vitreous cavity to avoid occlusion by the iris, and avoid tube kinking through the sclera that could reduce long-term control of IOP. Two eyes of 1 patient (patient 3) developed mild cystoid macular edema associated with epiretinal membrane at 1 year but maintained good visual acuity and did not require treatment. There were no other complications related to the surgical procedure. Of note, there were no cases of hypotony, retinal detachment, suprachoroidal hemorrhage, exposure of the tube or fluocinolone acetonide implant, or endophthalmitis. No patient required additional surgical procedures during the follow-up period.

COMMENT

The standard of care in the treatment of chronic noninfectious posterior uveitis has consisted of intraocular and periocular corticosteroid injections and systemic corticosteroid, immunomodulatory, and cytotoxic agents.1,2 These treatments are fraught with limitations. Systemic adverse effects (including hyperglycemia, blood dyscrasias, malignant neoplasm, sterility, and gastrointestinal ulceration) and minimal delivery to target intraocular tissue due to the blood ocular barrier limit the usefulness of systemic medications.1 Periocular and intraocular corticosteroid injections are limited by their relatively short duration requiring repeated injections and the risk of local complications, including endophthalmitis and globe perforation.1 Intravitreal fluocinolone acetonide implants circumvent these limitations by providing release of corticosteroid medication directly into the vitreous cavity, where it is most effective.35 In complicated cases of uveitis in which there is a preexisting cataract and elevated IOP or a history of strong corticosteroid response, it makes sense to address the cataract and elevated IOP at the time of fluocinolone acetonide implant insertion, particularly given the high rate of postimplant cataract and glaucoma surgery.3,6,7

Our study shows that CE and Ahmed valve PPT placement can be combined with a fluocinolone acetonide implant and PPV in a single surgical procedure with good anatomic and functional outcomes and no serious adverse effects. In fact, these patients may do better than those in whom the procedures are performed separately. Patients are spared the risks of anesthesia associated with multiple procedures as well as the inconvenience and cost. More important, the concomitant anti-inflammatory effects of fluocinolone acetonide implants may allow for more successful outcomes with both the CE/PCIOL and PPT, since many of the postoperative complications associated with these procedures are secondary to inflammation.9,11 These complications are largely avoided with the addition of fluocinolone acetonide implants, which provides excellent control of postoperative inflammation and significantly reduces the need for systemic, periocular, and topical corticosteroid therapy. For example, a high percentage (12%-46%) of patients with uveitis develop cystoid macular edema after CE, particularly when there is a recurrence of inflammation.1216 Fluocinolone acetonide implants can reduce cystoid macular edema in up to 73% of eyes that receive them.3

All our patients achieved excellent postoperative inflammatory control with no recurrences. We opted for slow postoperative tapering of oral corticosteroid therapy given that all eyes in our study represented very complicated advanced cases of posterior uveitis and performing a combined surgical procedure would be expected to result in a more severe inflammatory response than would be seen with fluocinolone acetonide implants alone.

Only 2 eyes in our study required any IOP-lowering treatments. These were the first 2 cases, which had anterior chamber tubes diverted to the pars plana. This may be explained by initial encapsulation around those tubes that may have affected long-term outcomes and resulted in decreased success with regard to controlling IOP compared with primary PPTs. However, those 2 eyes had the longest follow-up, and other primary PPTs may eventually show similar IOP responses. Nonetheless, we believe that the proximity of the PPT to the fluocinolone acetonide implant in the vitreous cavity may have a better long-term IOP outcome than anterior chamber tubes or trabeculectomies. Moreover, PPTs have the added benefit of sparing corneal endothelium, the loss of which is commonly seen in anterior chamber tubes.1719

Limitations of our study include its small sample size, retrospective design with lack of a control group, and relatively short follow-up. Prospective studies with larger sample sizes and longer follow-up are needed. However, our results are promising. All our patients had significantly improved visual acuity (preoperative range, 20/200 to hand motions and postoperative range, 20/20 to 20/40), with excellent postoperative inflammatory control without the use of topical and systemic corticosteroids, immunomodulatory drugs, and IOP-lowering agents. The CPR-PT combined procedure seems to be a good surgical option for eyes with advanced chronic noninfectious uveitis, cataract, and elevated IOP. At least in the short term, there are no major complications.

Back to top
Article Information

Correspondence: Tamer H. Mahmoud, MD, PhD, Vitreoretinal Surgery, Duke University Eye Center, Erwin Rd, Box 3802, Durham, NC 27710 (tamer.mahmoud@duke.edu).

Submitted for Publication: April 5, 2011; final revision received September 6, 2011; accepted September 7, 2011.

Author Contributions: Dr Mahmoud had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: None reported.

Funding/Support: This work was supported by an unrestricted grant from Research to Prevent Blindness, Inc.

REFERENCES
1.
Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW.Fluocinolone Acetonide Study Group.  Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.  Ophthalmology. 2010;117(3):567-575PubMedArticle
2.
Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The Multicenter Uveitis Steroid Treatment trial: rationale, design, and baseline characteristics.  Am J Ophthalmol. 2010;149(4):550-561PubMedArticle
3.
Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results.  Arch Ophthalmol. 2008;126(9):1191-1201PubMedArticle
4.
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T.Fluocinolone Acetonide Uveitis Study Group.  Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.  Ophthalmology. 2006;113(6):1020-1027PubMedArticle
5.
Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.  Ophthalmology. 2005;112(7):1192-1198PubMedArticle
6.
Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature.  Curr Opin Ophthalmol. 2006;17(2):163-167PubMed
7.
Goldstein DA, Godfrey DG, Hall A,  et al.  Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.  Arch Ophthalmol. 2007;125(11):1478-1485PubMedArticle
8.
Chieh JJ, Carlson AN, Jaffe GJ. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.  Am J Ophthalmol. 2008;146(4):589-594PubMedArticle
9.
Malone PE, Herndon LW, Muir KW, Jaffe GJ. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.  Am J Ophthalmol. 2010;149(5):800-806, e1PubMedArticleArticle
10.
Jabs DA, Nussenblatt RB, Rosenbaum JT.Standardization of Uveitis Nomenclature (SUN) Working Group.  Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop.  Am J Ophthalmol. 2005;140(3):509-516PubMedArticle
11.
Muccioli C, Belfort R Jr. Cataract surgery in patients with uveitis.  Int Ophthalmol Clin. 2000;40(2):163-173PubMedArticle
12.
Okhravi N, Lightman SL, Towler HM. Assessment of visual outcome after cataract surgery in patients with uveitis.  Ophthalmology. 1999;106(4):710-722PubMedArticle
13.
Foster RE, Lowder CY, Meisler DM, Zakov ZN. Extracapsular cataract extraction and posterior chamber intraocular lens implantation in uveitis patients.  Ophthalmology. 1992;99(8):1234-1241PubMed
14.
Rahman I, Jones NP. Long-term results of cataract extraction with intraocular lens implantation in patients with uveitis.  Eye (Lond). 2005;19(2):191-197PubMedArticle
15.
Estafanous MF, Lowder CY, Meisler DM, Chauhan R. Phacoemulsification cataract extraction and posterior chamber lens implantation in patients with uveitis.  Am J Ophthalmol. 2001;131(5):620-625PubMedArticle
16.
Belair ML, Kim SJ, Thorne JE,  et al.  Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography.  Am J Ophthalmol. 2009;148(1):128-135PubMedArticle
17.
Hau S, Barton K. Corneal complications of glaucoma surgery.  Curr Opin Ophthalmol. 2009;20(2):131-136PubMedArticle
18.
Lee EK, Yun YJ, Lee JE, Yim JH, Kim CS. Changes in corneal endothelial cells after Ahmed glaucoma valve implantation: 2-year follow-up.  Am J Ophthalmol. 2009;148(3):361-367PubMedArticle
19.
Sarkisian SR Jr. Tube shunt complications and their prevention.  Curr Opin Ophthalmol. 2009;20(2):126-130PubMedArticle
×